Solventum Corporation (NYSE:SOLV) Given Average Recommendation of “Moderate Buy” by Brokerages

Solventum Corporation (NYSE:SOLV) has received a consensus rating of “Moderate Buy” from the twelve research firms that are currently covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $93.70.

Several research analysts have recently weighed in on SOLV shares. Wall Street Zen cut Solventum from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Mizuho set a $100.00 price target on Solventum and gave the company an “outperform” rating in a report on Tuesday, January 20th. KeyCorp lifted their price objective on Solventum from $97.00 to $99.00 and gave the stock an “overweight” rating in a research report on Friday, February 27th. Stifel Nicolaus boosted their price objective on Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Finally, Zacks Research cut Solventum from a “strong-buy” rating to a “hold” rating in a report on Monday, December 1st.

Insiders Place Their Bets

In other news, Director Amy Mcbride Wendell purchased 1,475 shares of the company’s stock in a transaction dated Tuesday, March 10th. The stock was acquired at an average price of $68.03 per share, with a total value of $100,344.25. Following the purchase, the director directly owned 5,039 shares in the company, valued at approximately $342,803.17. This represents a 41.39% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 0.05% of the stock is owned by insiders.

Institutional Trading of Solventum

Institutional investors have recently made changes to their positions in the company. United Services Automobile Association purchased a new stake in Solventum in the 1st quarter valued at about $239,000. Woodline Partners LP boosted its stake in Solventum by 40.7% during the first quarter. Woodline Partners LP now owns 11,677 shares of the company’s stock worth $888,000 after buying an additional 3,377 shares during the period. Intech Investment Management LLC increased its position in shares of Solventum by 167.0% during the first quarter. Intech Investment Management LLC now owns 16,669 shares of the company’s stock valued at $1,268,000 after acquiring an additional 10,425 shares during the last quarter. Resona Asset Management Co. Ltd. increased its position in shares of Solventum by 2.0% during the second quarter. Resona Asset Management Co. Ltd. now owns 49,786 shares of the company’s stock valued at $3,773,000 after acquiring an additional 971 shares during the last quarter. Finally, Aviva PLC raised its stake in shares of Solventum by 6.8% in the 2nd quarter. Aviva PLC now owns 103,452 shares of the company’s stock valued at $7,846,000 after acquiring an additional 6,545 shares during the period.

Solventum Stock Performance

NYSE:SOLV opened at $66.76 on Wednesday. The company has a market cap of $11.58 billion, a P/E ratio of 7.53, a P/E/G ratio of 1.09 and a beta of 0.40. Solventum has a twelve month low of $60.70 and a twelve month high of $88.20. The company’s 50-day moving average price is $76.40 and its 200-day moving average price is $76.01. The company has a current ratio of 1.23, a quick ratio of 0.89 and a debt-to-equity ratio of 1.00.

Solventum (NYSE:SOLV) last announced its quarterly earnings data on Thursday, February 26th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.07. The company had revenue of $2 billion during the quarter, compared to analysts’ expectations of $1.96 billion. Solventum had a net margin of 18.69% and a return on equity of 25.26%. Solventum’s revenue was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.41 EPS. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. On average, sell-side analysts forecast that Solventum will post 6.58 earnings per share for the current fiscal year.

Solventum declared that its Board of Directors has approved a share repurchase program on Thursday, November 20th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the company to purchase up to 7.5% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.